This letter focuses on the diffusive molecular communication system with a reversible reactive receiver. By assuming the receiver is uniformly covered by finite receptors, a new boundary condition is proposed to model the reception reaction. In addition, an iterative approximation method is developed to model the expected received signal in this system. The simulation results verify the effectiveness of the approximation method.
This paper studies the molecular communication system where the transmitter has limited productivity and the receiver employs ligand-binding receptors. By simplifying the release and propagation process of the information particles, the ligand-binding process is regarded as a binding channel with peak and average constraints and modeled by a finite-state Markov chain. It is proved that the capacity of the constrained independent and identically distributed (IID) binding channel, defined as the IID capacity, is achieved by a discrete input distribution. The sufficient and necessary conditions of an IID input distribution being capacity-achieving is presented. Moreover, an algorithm called modified steepest ascent cutting-plane algorithm is proposed to efficiently compute the IID capacity-achieving distributions. The numerical results show that the IID capacity is a tight lower bound of the capacity for the binding channel.
26 September 2020 in IOP Conference Series: Earth and Environmental Science
Endothelial progenitor cells (EPCs) are circulating undifferentiated pluripotent cells capable of reconstituting endothelium in vivo and diminishing lesion formation following arterial injury. We tested the hypothesis that treatment with a specific soluble GSK 3β-inhibitor (GSK3βi) would improve the in vitro yield and function of EPCs from patients with coronary artery disease (CAD) and augment their in vivo potential to improve arterial repair after injury and stent implantation. In vitro treatment with GSK3βi at 1× (IC50) and 2× (IC50) increased the number of cells that dual labelled for acLDL and UEA-1 lectin on day 7 (13.4±3.2 vs. 39.9±5.3 vs. 43.8±10.1; p < 0.05). Furthermore, GSK3βi significantly augmented CAD-EPC survival to levels equal to those of healthy controls, increased VEGF secretion (7.1±1.6 vs 30.0±8.9, p<0.05) and resulted in a 4× increase in adhesion (p<0.05). Using Q-PCR, mRNA copy numbers for VLA-1,2,3,4 and 5 were assayed; however, only VLA-4 levels increased (4×, p<0.01). Use of a VLA-4 specific blocking antibody confirmed that the improved EPC adhesion was specifically mediated by VLA-4. Finally, the effects of GSK 3β inhibition were tested in two in vivo models of arterial injury. CD-1 athymic nude mice underwent femoral artery wire injury and injection of CAD-EPCs that were either GSK3βi treated, untreated, or injection with vehicle alone. GSK3βi treated EPCs improved the ability of xenotransplanted cells to inhibit lesion formation when compared to untreated and vehicle arteries respectively (intima/media ratios: 0.3±0.1 vs. 5.3±1.2 vs 11.2±2.7 μm, p<0.01). GSK3βi coated stents were inserted into rabbit carotid arteries. Fourteen days after stent deployment, GSK3βi stents resulted in a 44% increase in re-endothelialization (assessed by scanning electron microscopy and compared to vehicle coated stents; p<0.01) and a 16% trend towards a reduction in neointima formation (p<0.09). In summary, our data demonstrates that GSK3βi improves EPC function in vitro and ameliorates arterial repair following injury and stent insertion in vivo.